IMMP — IMMUTEP Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1506184 ·
Last close
$3.84
Market Cap
$565.91M
52W High
$8.20
52W Low
$0.26
ADV30
281,064
Next earnings
2026-09-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 83,267,229 | 63,672,558 | 21,734,183 |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | — | — | — | — | 147,201,896 | 72,747,858 | 48,303,108 |
| Mar 2025 | — | — | — | — | — | — | — |
Balance + Analyst (yfinance extras)
Retained Earnings
$-486,351,557
Inventory
—
Receivables
$37,520,366
ST Investments
$26,381,641
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$19,934,102
EBITDA
$-79,403,952
Free Cash Flow
$-36,994,360
Enterprise Value
$-12,811,502
Total Cash
$68,873,040
Total Debt
$1,047,526
Shares Out
147,372,131
Trailing EPS
$-0.39
Book Value
$0.30
ROE
-77.3%
ROA
-42.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 14,556,923 | -81,592,146 | -79,304,563 | 83,267,229 | 21,734,183 | 61,533,046 | — |
| Jun 2025 | — | — | — | — | — | — | — |
| Jun 2024 | 0 | -46,557,462 | -42,716,625 | 201,579,281 | 12,057,539 | 189,521,742 | — |
| Jun 2023 | 0 | -41,431,305 | -39,896,348 | 147,448,990 | 10,979,601 | 136,469,389 | — |
| Jun 2022 | 170,369 | -33,837,338 | -32,210,826 | 102,169,550 | 8,092,184 | 94,077,366 | -43,944,386 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.26
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| STTK | Shattuck Labs, Inc. | $568.06M | $5.66 | — |
| MNPR | Monopar Therapeutics | $563.69M | $83.98 | — |
| CRMD | CorMedix Inc. | $570.55M | $7.32 | — |
| EVO | Evotec SE | $557.96M | $1.57 | — |
| ACRS | Aclaris Therapeutics, Inc. | $557.88M | $3.79 | — |
News headlines (Yahoo Finance, 1h cache)
Immutep Receives ~A$0.86 Million R&D Tax Incentive
2026-09-30 12:00 · Yahoo
Change to American Depositary Share Ratio
2026-09-21 12:00 · Yahoo
Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
2026-09-11 12:00 · Yahoo
Immutep Quarterly Activities Report Q4 FY26
2026-07-30 12:00 · Yahoo
Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
2026-07-24 12:00 · Yahoo
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsi
2026-07-21 17:00 · Yahoo
Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
2026-07-14 12:00 · Yahoo
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
2026-07-13 12:00 · Yahoo
Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026
2026-06-04 12:00 · Yahoo
Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
2026-05-28 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.